KEYPAD

This study is designed to test the safety and potential benefit of adding an existing drug used for bone protection (denosumab) to a new immune stimulating drug (pembrolizumab).

Trial overview

Topic

Metastatic kidney cancer

Description

Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial (ANZUP1601) KidnEY cancer Pembrolizumab And Denosumab.

Eligibility criteria

Kidney Cancer after progression on first line treatment
No prior treatment with immunotherapy

Study details

The treatment is 3 weekly Pembrolizumab and Denosumab. While on treatment there will be regular blood tests and scans to monitor progress. At completion of treatment the study will continue to follow your progress.

Further information

For more information regarding this clinical trial click here.

Location

North Shore

Enquire

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.

First name *

Last name *

Email *

Phone *

State *

Postcode *

What is the reason for enquiry?

How would you prefer to be contacted? *

Phone

By submitting you acknowledge we will use the information you are providing to contact you about your enquiry. For more information about how we handle your personal information, please refer to the GenesisCare Privacy Policy.

KEYPAD

Trial overview

Thank you for submitting.

An unexpected error has occurred.

How can we help?

GenesisCare

Website policies

Contact us

Media & Social